AIM ImmunoTech

Liquidity at June 30, 2026 totaled about 10.0 million dollars in cash, cash equivalents and marketable investments against total liabilities of roughly 5.0 million dollars and a current portion of notes payable of about 3.6 million dollars.

Net cash outflow from operating activities for the first half of 2026 was approximately 7.3 million dollars, implying short runway without additional capital. The company again disclosed substantial doubt about its ability to continue as a going concern.

Equity issuance and warrant exercises have been the primary financing levers; an ATM facility was terminated in August 2026. Debt is present and near‑term maturities increase risk.